Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: A budget impact analysis

Clinical Therapeutics

Volumn 27, Issue 6, 2005, Pages 951-959

  Smith, Dean G ^a   Cerulli, Annamaria ^b   Frech, Feride H ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Novartis Pharmaceuticals Corporation ^*

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Budget impact; Heart failure; Hospital costs

Indexed keywords

AMLODIPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; VALSARTAN;

ADULT; AGED; ARTICLE; BUDGET; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DEMOGRAPHY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SIDE EFFECT;

EID: 27744455490     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.06.014     Document Type: Article

References (39)

1. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. Dallas, Tex: American Heart Association; 2004.
2. Lloyd-Jones DM, Larson MC, Leip EP, et al. Lifetime risk for developing congestive heart failure: The Framingham Heart Study. Circulation. 2002;106:3068-3072.
3. Litaker JR, Chou JY. Patterns of pharmacologic treatment of congestive heart failure in elderly nursing home residents and related issues: A review of the literature. Clin Ther. 2003;25:1918-1935.
4. Xuan J, Duong PT, Russo PA, et al. The economic burden of congestive heart failure in a managed care population. Am J Manag Care. 2000;6:693-700.
5. Tsuyuki RT, Shibata MC, Nilsson C, Hervas-Malo M. Contemporary burden of illness of congestive heart failure in Canada. Can J Cardiol. 2003;19:436-438.
6. Ryden-Bergsten T, Andersson F. The health care costs of heart failure in Sweden. J Intern Med. 1999;246:275-284.
7. Haldeman CA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J. 1999;137:352-360.
8. National Hospital Discharge Survey Data Highlights. Number of discharges from short-stay hospitals, by age and first-listed diagnosis: United States, 2001. Available at: http://www.cdc.gov/nchs/data/ hdasd/srl3_156t11.pdf. Accessed June 3, 2005.
9. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997;157:99-104.
10. Vavouranakis I, Lambrogiannakis E, Markakis G, et al. Effect of home-based intervention on hospital readmission and quality of life in middle-aged patients with severe congestive heart failure: A 12-month follow up study. Eur J Cardivasc Nurs. 2003;2:105-111.
11. Levy E. From cost of illness to costeffectiveness in heart failure. Eur Heart J. 1998;19(Suppl P):P2-P4.
12. Conn JN, Johnson C, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Eng J Med. 1991;325: 303-310.
13. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet. 1999;353:9-13.
14. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
15. Conn JN, Tognoni G, for the Valsartan Heart Failure Trial. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Eng J Med. 2001;345: 1667-1675.
16. Sica DA. ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure. 2004;10:160-164.
17. Maggioni AP, Anand I, Gottleib SO, et al, for the Val-HeFT Investigators (Valsartan Heart Failure Trial). Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Candiol. 2002:40:1414-1421.
18. US Bureau of the Census. Annual estimates of the population by sex and five-year age groups for the United States: April 1,2000, to July 1, 2003. Available at: http://www.census.gov/ popest/national/asrh/NC-EST2003/ NC-EST2003.pdf. Accessed June 3, 2005.
19. Calculating the CHF extra payment for 2003. Available at: http://cms.hhs. gov/Healthplans/CHF/calcxtrapy mnt2003.asp. Accessed August 6, 2003.
20. Bungard TJ, McAlister FA, Johnson JA, Tsuyuki RT. Underutilisation of ACE inhibitors in patients with congestive heart failure. Drugs. 2001;61: 2021-2033.
21. Jackson J, Farrelly E, Ziska D, et al. Heart failure therapies within managed care. Presented at: Annual Scientific Meeting of the Heart Failure Society of America; September 22-25, 2002; Boca Raton, Fla.
22. Stafford RS, Davidson SM, Davidson H, et al. Chronic disease medication use in managed care and indemnity insurance plans. Health Serv Res. 2003; 38:595-612.
23. Cazzola M, Noschese P, D'Amato G, Matera MC. The pharmacologiC treatment of uncomplicated arterial hypertension in patients with airway dysfunction. Chest. 2002;121:230-241.
24. Drug Topics Red Book. Montvale, NJ: Medical Economics Company; 2001.
25. Smith NL, Psaty BM, Pitt B, et al. Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting enzyme inhibitors in older adults, 1989 through 1995. Arch Intern Med. 1998; 158:1074-1080.
26. Pfeffer MA, McMurray JJ, Velazquez EJ, et al, for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [published correction appears in N Engl J Med. 2004; 350:203]. N Engl J Med. 2003;349: 1893-1906.
27. Malacco E, Santonastaso M, Van NA, et al, for the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: The Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study [published correction appears in Clin Ther. 2004;26: 1185 and Clin Ther. 2005;27:142]. Clin Ther. 2004;26:855-865.
28. Malacco E, Piazza S, Scandiani L, Zoppi A. Effects of valsartan/ hydrochlorothiazide and amlodipine on ambulatory blood pressure and plasma norepinephrine levels in high-risk hypertensive patients. Adv Ther. 2004:21:149-161.
29. Diovan [package insert]. East Hanover, NJ: Novartis Pharmaceutical Corporation; 2002.
30. Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass: Little, Brown & Co; 1994.
31. Cohn JN, Tognoni G, Glazer RD, et al. Rationale and design of the Valsartan Heart Failure Trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card fail. 1999;5:155-160.
32. Verdecchia P, Angeli F. Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. Clin Ther. 2004:26:460-472.
33. Velasquez EJ, Reed SD, Friedman JY, et al. Valsartan is cost-effectiveness in heart failure patients not receiving ACE inhibitors. Presented at: XXIV Congress of the European Society of Cardiology; August 31- September 4, 2002; Berlin, Germany.
34. DRC 127 heart failure and shock: All-payer summary information for short-term, general, nonfederal US hospitals. In: The DRC Handbook: Comparative Clinical and Financial Benchmarks. 12th ed. Evanston, III: Solucient LLC; 2002:212-214.
35. Hussey LC, Hardin S, Blanchette C. Outpatient costs of medications for patients with chronic heart failure. Am J Crit Care. 2002;11:474-478.
36. Psaty BM, Boineau R, Kuller LH, Luepker RV. The potential costs of upcoding for heart failure in the United States. Am J Cardiol. 1999;84: 108-109, A9.
37. Schwartz JS, Wang YR, Cleland JG, et al, for the ATLAS Study Group. High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: An economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial. Am J Manag Care. 2003:9:417-424.
38. Hunt SA, Baker DW, Chin MH, et al, for the American College of Cardiology/American Heart Association. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2001;38:2101-2113.
39. Discher CL, Klein D, Pierce L, et al. Heart failure disease management: Impact on hospital care, length of stay, and reimbursement. Congest Heart fail. 2003;9:77-83.